Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure

Pharmacology ◽  
2015 ◽  
Vol 96 (3-4) ◽  
pp. 184-191 ◽  
Author(s):  
Baigalmaa Lkhagva ◽  
Yung-Kuo Lin ◽  
Yu-Hsun Kao ◽  
Tze-Fan Chazo ◽  
Cheng-Chih Chung ◽  
...  
Keyword(s):  
Heart Failure ◽  
Histone Deacetylase ◽  
Inflammatory Cytokines ◽  
Histone Deacetylase Inhibitor ◽  
Peroxisome Proliferator ◽  
Deacetylase Inhibitor ◽  
Peroxisome Proliferator Activated Receptors

Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression

2004 ◽  
Vol 32 (5) ◽  
pp. 840-842 ◽  
Author(s):  
V.C. Emmans ◽  
H.A. Rodway ◽  
A.N. Hunt ◽  
K.A. Lillycrop
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Trichostatin A ◽  
Neuroblastoma Cells ◽  
Retinoblastoma Protein ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Cellular Processes ◽  
Deacetylase Inhibitor

Neuroblastoma is a childhood cancer, which spontaneously regresses. This has led to a search for agents that mimic this process. We show that both natural and synthetic ligands of PPARγ (peroxisome-proliferator-activated receptor γ) inhibit the growth of neuroblastoma cells in vitro. The degree of PPAR activation was attenuated however in the presence of the retinoblastoma protein. Addition of trichostatin A, a histone deacetylase inhibitor, abolished retinoblastoma protein repression of PPAR activity. Moreover, enhanced growth inhibition was observed when neuroblastoma cells were treated with a PPARγ ligand and a histone deacetylase inhibitor, suggesting a combination therapy to treat neuroblastoma might prove more effective than using either agent alone.

scholarly journals Suppression of Adiponectin Gene Expression by Histone Deacetylase Inhibitor Valproic Acid

Endocrinology ◽  
2006 ◽  
Vol 147 (2) ◽  
pp. 865-874 ◽  
Author(s):  
Liping Qiao ◽  
Jerome Schaack ◽  
Jianhua Shao
Keyword(s):  
Gene Expression ◽  
Valproic Acid ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Binding Protein ◽  
Peroxisome Proliferator ◽  
Mrna Levels ◽  
Adiponectin Gene ◽  
Peroxisome Proliferator Activated Receptor ◽  
Deacetylase Inhibitor

Valproic acid (VPA) has been used for the treatment of epilepsy and bipolar disorders for more than 30 yr. Obesity and insulin resistance are common side effects of VPA treatment. Adiponectin is an adipocyte-derived protein that plays an important role in controlling insulin sensitivity and glucose homeostasis. In this report, we examined the effects of VPA on adiponectin gene expression in C57BL/6J mice and in differentiated 3T3-L1 adipocytes. VPA treatment significantly decreased adiponectin protein and mRNA levels in both mice and 3T3-L1 adipocytes. The adipocyte study showed that VPA inhibited adiponectin gene expression in a dose- and time-dependent manner. Repression of adiponectin expression by VPA occurred at the transcription level and correlated with inhibition of histone deacetylase activity. Therapeutic concentrations of VPA increased overall histone acetylation and increased adiponectin promoter-driven luciferase expression in fibroblasts, but decreased adiponectin promoter activity in differentiated 3T3-L1 adipocytes. VPA treatment decreased adipogenic transcription factor CCAAT/enhancer binding protein-α (C/EBPα) levels and binding of C/EBPα to the adiponectin promoter without altering the levels of peroxisome proliferator-activated receptor-γ and steroid regulatory element binding protein-1. Furthermore, VPA did not suppress adiponectin gene expression in C/EBPα gene-deficient adipocytes that stably expressed exogenous peroxisome proliferator-activated receptor-γ2. Together, these results demonstrate that histone deacetylase inhibitor VPA suppresses adiponectin gene expression in mature adipocytes. The study also provides evidence that diminished C/EBPα protein level and decreased binding at the adiponectin promoter mediate the inhibitory effects of VPA on adiponectin gene transcription.

scholarly journals Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Jing Ma ◽  
Tao Luo ◽  
Zhi Zeng ◽  
Haiying Fu ◽  
Yoshihiro Asano ◽  
...  
Keyword(s):  
Heart Failure ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Hdac Inhibition ◽  
Deacetylase Inhibitor

scholarly journals The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo

2005 ◽  
Vol 11 (1-12) ◽  
pp. 1-15 ◽  
Author(s):  
Flavio Leoni ◽  
Gianluca Fossati ◽  
Eli C Lewis ◽  
Jae-Kwon Lee ◽  
Giulia Porro ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Inflammatory Cytokines ◽  
Systemic Inflammation ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor ◽  
Pro Inflammatory Cytokines

Induction of apoptosis in hepatocellular carcinoma by a novel combination of histone deacetylase inhibitor LBH589

2020 ◽  
Author(s):  
P Mester ◽  
E Aschenbrenner ◽  
C Kunst ◽  
K Gülow ◽  
M Müller-Schilling
Keyword(s):  
Hepatocellular Carcinoma ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor ◽  
Induction Of Apoptosis
Sign in / Sign up

Export Citation Format

Share Document